The LDN Book

How a Little-Known Generic Drug — Low Dose Naltrexone — Could Revolutionize Treatment for Autoimmune Diseases, Cancer, Autism, Depression, and More

• Author(s): Linda Elsegood,
• Publisher: Chelsea Green Publishing
• Pages: 240
• ISBN_10: 1603586652
  ISBN_13: 9781603586658
  
• Language: en
• Categories: Medical / Alternative & Complementary Medicine , Health & Fitness / Diseases & Conditions / Immune & Autoimmune , Health & Fitness / Diseases & Conditions / Cancer , Health & Fitness / Alternative Therapies , Health & Fitness / Diseases & Conditions / Chronic Fatigue Syndrome , Psychology / Psychopathology / Autism Spectrum Disorders , Medical / Diseases , Medical / Pharmacology , Family & Relationships / Autism Spectrum Disorders , Health & Fitness / Diseases & Conditions / General , Medical / Immunology , Medical / Oncology / General , Psychology / Developmental / Child ,

Description:...

Could a little-known drug really revolutionize treatment for autoimmune diseases, cancer, depression, and more?

“[LDN] raises hopes of reversing memory loss in old age.”—the Guardian

Over 30,000 copies sold!

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even autism, chronic fatigue, and depression, find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects.

So why has it languished in relative medical obscurity?

The LDN Book explains:

• The drug’s origins
• Its primary mechanism
• The latest research from practicing physicians and pharmacists

Compiled by Linda Elsegood of The LDN Research Trust—the world’s largest LDN charity organization with over 19,000 members worldwide—the book features ten chapters contributed by medical professionals on LDN’s efficacy and two patient-friendly appendices.

The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.